ImmuPharma plc (LON:IMM – Get Free Report)’s share price was up 9.8% during mid-day trading on Wednesday . The company traded as high as GBX 3.75 and last traded at GBX 3.75. Approximately 879,750 shares were traded during mid-day trading, a decline of 65% from the average session volume of 2,526,928 shares. The stock had previously closed at GBX 3.41.
ImmuPharma Stock Up 3.2%
The stock has a market cap of £22.53 million, a price-to-earnings ratio of -9.76 and a beta of 3.01. The company has a 50 day simple moving average of GBX 3.93 and a 200 day simple moving average of GBX 4.86.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. As a group, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
